Completed PHASE3 INTERVENTIONAL 1-arm NCT01329887

The Effect of Ketanserin on the Microcirculation in Sepsis

Evaluation of the Effect of Ketanserine on Sublingual Microcirculation by SDF Imaging in Septic Patients on the Intensive Care

Sponsor: Frisius Medisch Centrum

Conditions Septic Shock Severe Sepsis

Interventions ketanserin

Updated 6 times since 2017 Last updated: May 8, 2014 Started: Mar 31, 2011 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01329887, this PHASE3 trial focuses on Septic Shock and Severe Sepsis and remains completed. Sponsored by Frisius Medisch Centrum, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Jun 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Jun 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Frisius Medisch Centrum

Data source: Frisius Medisch Centrum

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leeuwarden, Netherlands